Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. - Wikidata - wikimedia - TriplyDB

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

http://www.wikidata.org/entity/Q34410885

about

Everolimus in the Treatment of Metastatic Breast Cancer Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study.Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.The Promoting Effect of Radiation on Glucose Metabolism in Breast Cancer Cells under the Treatment of Cobalt Chloride.The therapeutic potential of mTOR inhibitors in breast cancer.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer.Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups Community pharmacist-led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer.Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.

P2860

Q26784920-10DB3684-1CCB-41BB-A3D4-D0ACCC2C392E Q28085004-246D3363-A25B-4284-BAB0-CCB8D2362DCB Q31132241-124AF066-C1EE-4D2B-9AF1-9CDAD54C1312 Q33441090-D16C699E-4004-4023-AC2E-EC05187028E7 Q34547982-09432791-0E29-4BD5-AC00-C5470A856507 Q35736115-4263A110-1D32-4995-AF79-21C197E592AA Q36078905-9AE8ABEE-AD90-4A7C-897F-DFAA683AD145 Q36337416-8D053F7D-0A83-489B-BC02-54CFC8464FAC Q37074917-CB741542-027C-40FC-8CEC-BE9239C359A7 Q37255106-5A176A2A-652C-43D5-AE23-123251324322 Q37534910-FE294A22-0ABF-4059-8871-34670469FE9E Q37600837-392FF326-C521-4708-AEAA-10C74E6BA62B Q37671961-2E6B142D-8BFF-41BE-BBF9-8021E52747D8 Q37748071-6DF97C22-324E-413E-A405-CEA16A5CDDF6 Q38093128-EB7FA53A-6594-4BC0-BE22-6EADB7B5D130 Q38603164-BF131E9B-F51E-45F8-9473-FE66528ECADC Q38762365-61B5463F-A598-45E8-BD1C-7AE18F85BE27 Q38802412-D4356B42-F25E-42EF-AAC1-394CCB0988E4 Q38882776-1FF89FBA-C6AA-4CCB-B556-B0A4842126CC Q41078931-AF19C8A0-C90C-412C-BCD3-EFB2F545779D Q41630845-49A82BF6-7005-4C27-BE3B-5EA570AA25D0 Q42346622-3BA01E95-CBDB-45AC-B385-0316E151D03F Q47107266-367D8DF3-E5C2-4488-AF5B-186076927C28 Q48306032-DBC553EF-03BE-45EB-B3A4-BCAE3559B9CC Q49970203-2449F03C-2D11-4169-9074-A6276290AB38 Q51670690-71DE276C-F756-4E54-A92C-0BCC17C01C91 Q54349937-2337F2D3-E931-41CD-BE17-A1331089ED73

P2860

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

http://www.wikidata.org/entity/Q34410885

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@ast

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@en

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@nl

type

label

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@ast

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@en

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@nl

prefLabel

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@ast

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@en

Efficacy of everolimus with ex ...... ive breast cancer in BOLERO-2.

@nl

P1433

Q34410885-4C919BAC-6126-4105-85BE-6A5CF90D2B41

P1476

Q34410885-339DCA3C-AF2E-4410-952B-72281666F2E5

P2093

Q34410885-0791DC14-F99E-44D0-BD36-F943308EFF13

Q34410885-0BBADEF5-42BA-4FD5-90D3-2E881CD097F7

Q34410885-20298454-E9A4-4819-A064-1DEDC2E59F34

Q34410885-3961BAEA-805C-4AED-B474-90DCD1CCBD4D

Q34410885-3B9E9645-5A92-4BD9-927B-9E851B11F3CA

Q34410885-455F1421-1065-451F-930A-B9403EB9B541

Q34410885-55BF31D4-C936-47DC-B0E6-A182F5E1C6B0

Q34410885-84D2AFBB-F3FF-4202-83FD-A6D01403F3E5

Q34410885-8B8990FA-0694-4C99-9917-BB05F04AB776

Q34410885-95A7B7A6-8788-4AB1-925A-A0A66220E2B0

P2860

Q34410885-080390D5-0DA3-4275-AD36-58AD4538BD89

Q34410885-4F5371AE-6FE0-47BC-B844-96C1CEC2BC5F

Q34410885-589866C3-73A5-4478-9260-9CD6A4C2CBE7

Q34410885-74FCD427-664A-4BB9-99D4-E24BD867E34A

Q34410885-892077AA-75BA-4AC6-9B49-35CA8966E373

Q34410885-8BFB6120-DE35-43F1-A291-838779AAB0A1

Q34410885-90110025-FF16-4E82-B5A8-A5C219CE3322

Q34410885-9B833A01-257F-498A-A9F6-25768BC796D7

Q34410885-A753F179-3731-411D-B386-766F82BD5179

Q34410885-AECACA44-6D42-43E0-AC08-D859AC902377

P2888

Q34410885-57054C9B-0664-43A9-9442-85439D34F18B

P304

Q34410885-7342C9F0-B5F2-4F13-9779-5A26EB72CC6D

P31

Q34410885-D6CA931B-8E20-4CE7-9CB1-E603FD93461B

P356

Q34410885-5C2D5C3F-1BC5-4BA3-BA68-FF872B10D41D

P433

Q34410885-3D6FA1A0-9242-4805-8F9F-701EF0939178

P478

Q34410885-1F0C85F9-48A1-4003-80C5-C48171928599

P50

Q34410885-ECBCD3EF-80D0-44EE-BD27-AE98BEA907B4

P577

Q34410885-EE4240DB-93E6-4B7D-A5C7-9AB46D643D53

P5875

Q34410885-AEB17C18-A6C8-43C6-8CDC-06E833B73295

P6179

Q34410885-30D95043-579A-4797-900F-F159EA088772

P698

Q34410885-67B28F77-E651-4EF5-88FC-CAC80239AC34

P932

Q34410885-F0C1E841-2AEB-4ECD-AA1F-8A7F0A739C28

P356

S12282-013-0444-8

P1433

P1476

Efficacy of everolimus with ex ...... tive breast cancer in BOLERO-2

@en

P2093

Ashok Panneerselvam

http://www.w3.org/2001/XMLSchema#string

Hideo Inaji

http://www.w3.org/2001/XMLSchema#string

Hirofumi Mukai

http://www.w3.org/2001/XMLSchema#string

Hiroji Iwata

http://www.w3.org/2001/XMLSchema#string

Hirotaka Iwase

http://www.w3.org/2001/XMLSchema#string

Jun Horiguchi

http://www.w3.org/2001/XMLSchema#string

Katsumasa Kuroi

http://www.w3.org/2001/XMLSchema#string

Mona El-Hashimy

http://www.w3.org/2001/XMLSchema#string

Norikazu Masuda

http://www.w3.org/2001/XMLSchema#string

Puttisak Puttawibul

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Molecular basis of ethnic differences in drug disposition and response.

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

P2888

s12282-013-0444-8

P304

703-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12282-013-0444-8

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Byeong-Woo Park

P577

2013-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235604449

http://www.w3.org/2001/XMLSchema#string

P6179

1018435401

http://www.w3.org/2001/XMLSchema#string

P698

23404211

http://www.w3.org/2001/XMLSchema#string

P932

4210660

http://www.w3.org/2001/XMLSchema#string